ALTIMMUNE INC (ALT)

3 Speculative Weight Loss Drug Stocks to Bet On for Big Gains

These weight loss drug stocks are relatively unknown and brimming with potential following the massive success of Novo Nordisk and Eli Lilly.

Missed Out on Eli Lilly and Novo Nordisk? This Small Biotech Has a Promising GLP-1 Drug With Significant Potential

Altimmune has a modest market cap but an incredibly promising GLP-1 drug.

Interesting ALT Put And Call Options For December 20th

Altimmune is Now Oversold (ALT)

First Week of May 31st Options Trading For Altimmune (ALT)

3 Biotech Stocks to Turn $5,000 Into $1 Million: April 2024

Biotech stocks can offer some of the most explosive, exciting opportunities on the market.That is, if you find the right one.

Forget Viking Therapeutics. Here's 1 Weight-Loss Stock to Keep Your Eyes on Instead.

Viking Therapeutics has garnered a lot of attention following a successful clinical trial for its obesity care drug. But another development-stage biotech may have a superior candidate.

Stock Market Rally Shows Breadth As Leaders Take A Breath: Weekly Review

The stock market rally showed breadth, with small caps leading the way to a 24-month high. Growth leaders like Nvidia took a break.

ALT Stock Earnings: Altimmune Beats EPS for Q4 2023

ALT stock results show that Altimmune beat analyst estimates for earnings per share the fourth quarter of 2023.

ALT Stock Earnings: Altimmune Beats EPS for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Altimmune (NASDAQ:ALT) just reported results for the fourth quarter of 2023.Alt...

Altimmune Announces Positive Lean Mass Preservation Data for Pemvidutide and Reports Fourth Quarter and Full Year 2023 Financial Results

Body composition study showed lean mass preservation, with only 25.5% of weight loss derived from lean mass Enrollment ongoing in IMPACT Phase...

Altimmune Obesity Drug Sheds Fat With Less Muscle Loss in Trial

Altimmune Inc.’s experimental weight-loss drug minimized muscle decline in a mid-stage trial, a sign that it can address a problem obesity drugmakers have been racing to solve.

Altimmune to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 27, 2024

GAITHERSBURG, Md., March 20, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it...

First Week of ALT May 17th Options Trading

Should Pfizer Acquire Viking Therapeutics to Take on Eli Lilly and Novo Nordisk in the Obesity Drug Market?

Viking Therapeutics just might be an attractive acquisition target for Pfizer.

ROSEN, A LONGSTANDING LAW FIRM, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALT

/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of...

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALT

WHY: NEW YORK, NY - (NewMediaWire) - March 03, 2024 - Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Altimmune, Inc. (NASDAQ: ALT) resulting from allegations that Altimmune may have issued materially misleading business information to the investing public.

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALT

WHY: NEW YORK, NY - (NewMediaWire) - March 03, 2024 - Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Altimmune, Inc. (NASDAQ: ALT) resulting from allegations that Altimmune may have issued materially misleading business information to the investing public.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Altimmune, Inc. - ALT

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT). Such investors...

ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALT

WHY: NEW YORK, NY - (NewMediaWire) - March 01, 2024 - Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Altimmune, Inc. (NASDAQ: ALT) resulting from allegations that Altimmune may have issued materially misleading business information to the investing public.

ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALT

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Stock Market Rally At Highs After Big Earnings, Inflation Data: Weekly Review

The Nasdaq is on the cusp of setting a record high.

Altimmune stock price forecast: brace for more ALT volatility

Altimmune (NASDAQ: ALT) stock price continued its short squeeze this week, soaring to a high of $14.52, its highest point since February 6th last year. The company’s stock surged by more than 580% from its lowest level in 2023. This surge has brought its total market cap to over $608 million. Short squeeze continues ALT […]

ALT LOSS ALERT: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALT

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.